SCHEMBL16508188

SCHEMBL16508188

Nc1ccc(S(=O)(=O)O)c2ccncc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.56
KAT2B Q92831 1/20 0.56
KAT8 Q9H7Z6 1/20 0.56
TTR P02766 1/20 0.51
AXL P30530 1/20 0.51
AURKA O14965 1/20 0.45
AURKB Q96GD4 1/20 0.45
CYP1A2 P05177 2/20 0.41
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
IMPDH2 P12268 3/20 0.39
COMT P21964 1/20 0.38
NAPRT Q6XQN6 1/20 0.38
KDM4E B2RXH2 2/20 0.38
CSNK1A1 P48729 1/20 0.38
CSNK1D P48730 1/20 0.38
CSNK1E P49674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30842108 0.87 NAPRT (0.44) EP300KAT2BKAT8TTRAURKA
SCHEMBL20836182 0.87 NAPRT (0.44) EP300KAT2BKAT8TTRAURKA
SCHEMBL8031733 0.85 NAPRT (0.42) EP300KAT2BKAT8TTRAURKA
SCHEMBL1491302 0.79 POLB (0.38) TTRCYP1A2COMTNAPRTCSNK1A1
SCHEMBL5894746 0.77 AXL (0.72) EP300KAT2BKAT8AXLCYP1A2
SCHEMBL5355239 0.76 AXL (0.51) TTRAXLCYP1A2COMTNAPRT
SCHEMBL30987405 0.76 AXL (0.51) TTRAXLCYP1A2COMTNAPRT
SCHEMBL1525888 0.76 TTR (0.78) EP300KAT2BKAT8TTRAURKA
SCHEMBL4808842 0.76 CA12 (0.44) EP300KAT2BKAT8TTRNAPRT
SCHEMBL29516385 0.76 TTR (0.78) EP300KAT2BKAT8TTRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294789-A1 COMPOUNDS FOR RHO KINASE INHIBITION AND FOR IMPROVING LEARNING AND MEMORY AMNESTIX, INC. 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294789-A1 COMPOUNDS FOR RHO KINASE INHIBITION AND FOR IMPROVING LEARNING AND MEMORY ROCK1, IRAK1, ROCK2 EP300 799/4885KAT2B 1656/4885KAT8 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.